Definium Therapeutics
Market cap $4.02B 136.9M shares (10-Q, Nov 2, 2026) × $29.38 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- DT402 R-MDMA interim2026DT402 R-MDMA interim, 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
R(-)-MDMA
DT402Capital (as filed)
- Cash
- $241M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $806M Sep 30, 2026
- Operating cash flow
- −$53.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $1.05B cash, runway 2030 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-06-24 424B5 · Priced offering 20.6M shares · at $34.00 · $700M gross · 6.0% below the prior close ($36.18, Jun 23, 2026)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (11)
- 2026-11-10 UPDATE: Definium (DFTX) - The Sleeper Asset Rolls Over 🔒 Paid
- 2026-09-15 UPDATE: Definium (DFTX) - Panorama Hits, And the Unblinding Elephant Finally Gets Answered 🔒 Paid
- 2026-09-08 UPDATE: Definium (DFTX) - A Second Breakthrough, And a Stock That Keeps Bleeding 🔒 Paid
- 2026-08-13 UPDATE: Definium (DFTX) - Voyage Hits, And the Stock Sells Off Anyway 🔒 Paid
- 2026-08-07 UPDATE: Definium (DFTX) - Voyage Lands Next Week, And They Quietly Bought Out Their Royalty 🔒 Paid
- 2026-06-24 UPDATE: Definium (DFTX) - The Raise Got Upsized, And The Greenshoe Cleared Same-Day 🔒 Paid
- 2026-06-22 UPDATE: Definium (DFTX) - Emerge Hits, And They Hit the Market 🔒 Paid
- 2026-05-08 UPDATE: Definium (DFTX) - The Pre-Readout Setup Locks In, PTSD Joins the Party 🔒 Paid
- 2026-04-27 UPDATE: Definium (DFTX) - The DEA Cloud Lifts and the Stats Get Sharper 🔒 Paid
- 2026-02-28 UPDATE: Definium (DFTX) Q4 Financial Update 🔒 Paid
- 2026-01-14 Definium Therapeutics, formerly MindMed (DFTX, formerly MNMD): Scientific Deep Dive for DT120 and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (11 calls)
Every verdict Biotech Distilled has published on Definium Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-01-14 Speculative buy core Definium Therapeutics, formerly MindMed (DFTX, formerly MNMD): Scientific Deep Dive for DT120 and Pipeline Products Strong Phase 2b data, secured cash runway into 2028, and asymmetric upside heading into three pivotal 2026 readouts justify a speculative buy sized for a potential 50-70% loss.
- 2026-02-28 Hold UPDATE: Definium (DFTX) Q4 Financial Update Thesis tracking perfectly with secure cash, strong institutional positioning, and MDD now leading the catalyst calendar; maintain and accumulate.
- 2026-04-27 Buy core UPDATE: Definium (DFTX) - The DEA Cloud Lifts and the Stats Get Sharper Executive Order materially de-risks DEA rescheduling overhang and Panorama SSRE results dramatically lower the statistical bar for a Phase 3 win, upgrading from speculative to core accumulate.
- 2026-05-08 Buy core UPDATE: Definium (DFTX) - The Pre-Readout Setup Locks In, PTSD Joins the Party Cash intact, catalyst calendar tightened to three pivotals in five months, and PTSD expansion signals internal confidence; maintain buy and accumulate into the Emerge MDD readout.
- 2026-06-22 Hold UPDATE: Definium (DFTX) - Emerge Hits, And They Hit the Market Emerge Phase 3 MDD delivered an 8.1-point placebo-adjusted MADRS delta validating the clinical thesis; mechanically trim post-data gains to take cost basis off the table while holding core through remaining pivotals.
- 2026-06-24 Hold UPDATE: Definium (DFTX) - The Raise Got Upsized, And The Greenshoe Cleared Same-Day $805M raise at favorable terms removes all financing overhang through NDA and launch; maintain trim-to-core stance with two binary pivotals still ahead in Q3.
- 2026-08-07 Buy core UPDATE: Definium (DFTX) - Voyage Lands Next Week, And They Quietly Bought Out Their Royalty $1.1B cash with runway into 2030, royalty burden permanently retired via Liechti Lab license buyout, and Voyage GAD pivotal readout imminent; maintain buy on the core position.
- 2026-08-13 Buy core UPDATE: Definium (DFTX) - Voyage Hits, And the Stock Sells Off Anyway Voyage delivered an exact Phase 2b replication (d=0.81) confirming the GAD signal; 7.3% selloff is profit-taking not a science verdict, maintain buy with Panorama as the final binary.
- 2026-09-08 Buy core UPDATE: Definium (DFTX) - A Second Breakthrough, And a Stock That Keeps Bleeding Second FDA Breakthrough Therapy designation in MDD confirms franchise engagement and compresses NDA timeline; 10.7% tape drift is positioning ahead of Panorama, not a science repricing.
- 2026-09-15 Hold UPDATE: Definium (DFTX) - Panorama Hits, And the Unblinding Elephant Finally Gets Answered Panorama's active-controlled design answered the functional unblinding objection with a clear dose-response gradient; clinical thesis is now substantially closed and the story shifts to commercial execution and DEA rescheduling.
- 2026-11-10 Hold UPDATE: Definium (DFTX) - The Sleeper Asset Rolls Over DT402 autism readout was only five open-label patients with no quantitative data and next study pushed to 2027; DT120 NDA on track but story is now a waiting game on regulatory and commercial execution.
- Long call · opened Jan 14, 2026 at $15.02 · +95.6% vs XBI +14.6% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (4 quotes from 4 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Panorama Topline Results | September 2026 2 Disclaimer Opening Remarks Rob Barrow Chief Executive Officer Thank you to our study participants, investigators and partners who made Panorama possible Significant need for innovation in the treatment of GAD 5 Population prevalence increased from 3% to 10% over last 20 years 1 No new drugs approved for GAD since 2007 Significant disease burden , with impairment in daily functioning, work productivity and quality of life Panorama Topline Results | September 2026 1.”
matched to DT120 (Panorama, Phase 3 GAD) · topline data
-
-
-
“AE: adverse event; CGI - S: Clinical Global Impression - Severity Scale; MADRS: Montgomery - Åsberg Depression Rating Scale; MDD: major depressive disorder; ODT: orally disintegrating tablet; SAEs: serious adverse events Voyage Topline Results | August 2026 8 Continuing to Build Potentially Practice - Changing Evidence 1 1.”
matched to DT120 (Emerge, Phase 3 MDD) · topline data
-
-
-
“Topline data anticipated the week of August 10, 2026.”
matched to DT120 (Panorama, Phase 3 GAD) · topline data
-
-
-
“Topline data anticipated the week of August 10, 2026.”
matched to DT120 (Ascend, Phase 3 MDD) · trial initiation / matched to DT120 (Panorama, Phase 3 GAD) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (41)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseDefinium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q and earnings release, filed after today's close, deliver the first human efficacy signal from DT402 (the R-MDMA "sleeper asset" in autism), confirm $1.05B cash with runway into 2030, and show commercial-preparedness spend accelerating — the thesis is transitioning from clinical to commercial, right on schedule.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseDefinium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Nov 3, 2026ReleaseDefinium Therapeutics to Participate at Upcoming Investor Conferences
- Oct 29, 2026ReleaseDefinium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
- Sep 14, 2026ReleaseDefinium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder→ BD updateSummary on the 8-K
- Sep 14, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updatePanorama hit — the GAD active-control study that I called the "single most important design choice in the entire Phase 3 program" delivered a positive readout today (d=0.64, p<0.0001), directly answering the functional unblinding objection while opening the NDA runway. Three-for-three on pivotals; the last domino has fallen.BD extracted 1 program update from this document → DFTX pipeline
- Sep 13, 2026ReleaseDefinium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026→ BD updateSummary on the 8-K of Sep 14, 2026BD extracted 1 program update from this document → DFTX pipeline
- Sep 10, 2026ReleaseDefinium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026BD extracted 1 program update from this document → DFTX pipeline
- Sep 8, 2026ReleaseDefinium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results→ BD updateSummary on the 8-K
- Sep 8, 20268-KCurrent report: other events · EX-99.1→ BD updateThe FDA just handed Definium its second Breakthrough Therapy Designation — this time for MDD, on the strength of the Emerge Phase 3 data — as the stock sits 10.7% below the Voyage-hit high with Panorama weeks away.BD extracted 1 program update from this document → DFTX pipeline
- Aug 26, 2026ReleaseDefinium Therapeutics to Participate at Upcoming Investor Conferences and Events
- Aug 12, 2026ReleaseDefinium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety DisorderBD extracted 1 program update from this document → DFTX pipeline
- Aug 12, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Aug 6, 2026ReleaseDefinium Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsBD extracted 1 program update from this document → DFTX pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jul 30, 2026ReleaseDefinium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Jul 16, 2026ReleaseDefinium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- Jul 14, 2026ReleaseNew Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Jun 25, 2026ReleaseDefinium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Jun 24, 20268-KCurrent report: material agreement, other events · EX-99.1 EXHIBIT 99.1
- Jun 24, 2026424B5Prospectus supplement (offering)
- Jun 23, 2026ReleaseDefinium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
- Jun 22, 2026ReleaseDefinium Therapeutics, Inc. Announces Proposed Public Offering
- Jun 22, 2026ReleaseDefinium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive DisorderBD extracted 1 program update from this document → DFTX pipeline
- Jun 22, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
- Jun 22, 2026424B5Prospectus supplement (offering)
- Jun 21, 2026ReleaseDefinium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026BD extracted 1 program update from this document → DFTX pipeline
- Jun 12, 20268-KCurrent report: officer / director change, shareholder vote
- May 21, 2026ReleaseDefinium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- May 19, 20268-KCurrent report: other events · EX-99.1
- May 12, 2026ReleaseDefinium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- May 12, 20268-KCurrent report: other events · EX-99.1
- May 7, 2026ReleaseDefinium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 27, 2026DEFA14AProxy soliciting material
- Apr 27, 2026DEF 14AProxy statement
- Apr 22, 20268-KCurrent report: other events · EX-99.1
7 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 5, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Jun 16, 2026S-8Employee plan registration
- May 15, 2026SCHEDULE 13G/A13G amendment